Aimee Crago is an Oncology physician affiliated with Memorial Sloan Kettering Cancer Center. OpenAlex indexes 274 publications with 6,877 citations (h-index 37); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1233 York Ave
Box 435
New York, NY 100656306
Telephone
617-792-6484Registry record last updated 16 Jun 2008.
Clinical trials
- Observing People With Desmoid-Type Fibromatosis
Sponsor: Memorial Sloan Kettering Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Deciphera Pharmaceuticals Inc.Program year20246 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
100%Nitroimidazole Antimicrobial100%Metronidazole100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2020–2024 per NIH RePORTER. The latest:
- Investigating HIF1-alpha Signaling to Identify Predictive Markers and Therapeutic Targets in Desmoid-Type Fibromatosis
Sloan-Kettering Inst Can Research
FY2024$530,202R37CA241856 - Investigating HIF1-alpha Signaling to Identify Predictive Markers and Therapeutic Targets in Desmoid-Type Fibromatosis
Sloan-Kettering Inst Can Research
FY2023$546,945R37CA241856 - Investigating HIF1-alpha Signaling to Identify Predictive Markers and Therapeutic Targets in Desmoid-Type Fibromatosis
Sloan-Kettering Inst Can Research
FY2022$558,108R37CA241856
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
Clinical Cancer Research
2023 - Management of Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma
Surgical Oncology Clinics of North America
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Valerie Rusch, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”